GSk and Daiichi Sankyo will both have an equal stake and split profits 50/50 of the new vaccines company which will be called Japan Vaccine Co. Both pharma companies will be selling their own vaccines to the company.
The aim of the 50/50 venture is to bring new vaccines to Japan – a market which has traditionally dealt more with treatment rather than prevention. The venture is due to start in July 2012 and will sell vaccines that are already being marketed to Japan by Daiichi and Glaxo. The plan is to then expand the business as new vaccines in the development pipeline are approved.
Speaking of the collaboration, Christopher Weber, president-designate of GSK Vaccines, stated that this “marks another step in our strategy to build our presence in key growth markets and will create the first and largest company dedicated solely to vaccines in Japan”. He adds that setting up the JV “will create further significant economies of scale in the development and distribution of vaccines in the Japanese market”.
Register your CV with us today!
Looking for a new position in the UK or EU Pharmaceutical Industry? Click here to register your CV with us today.
Once registered, one of our specialist Consultants will be in contact to discuss your requirements and any relevant positions we may be recruiting for.